ELECTROMED INC (ELMD)
Health Care · Medical devices for respiratory care · NYSE American
Electromed provides innovative airway clearance therapy through its SmartVest systems to help patients with chronic pulmonary conditions breathe easier.
What ELECTROMED INC does
Electromed, Inc. designs, manufactures, and markets the SmartVest Airway Clearance System, a therapeutic device that uses high-frequency chest-wall oscillation (HFCWO) technology to help patients with chronic respiratory conditions clear secretions from their airways. The company serves patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), and other conditions requiring airway management. Revenue is generated through device sales, accessories, and related respiratory care products distributed through healthcare providers and patient channels.
Themes: respiratory therapy, pulmonary health, home healthcare equipment, chronic disease management
Fundamentals
- Price$39.45 as of 2026-08-21 close
- Market cap$327M as of 2026-08-21
- 1-year return+107.4% 2025-08-21 close $19.02 → 2026-08-21 close $39.45
- P/E34.86 as of 2026-08-24
- Net margin+14.1% as of 2026-08-24
- Gross margin+78.4% as of 2026-08-24
- ROE+22.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+16.8% as of 2026-08-24
- Revenue CAGR (3y)+15.4% SEC XBRL
- Beta0.44 as of 2026-08-24
- Last reported earnings2026-05-12 SEC EDGAR Form 8-K (Item 2.02)
How ELMD compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ELECTROMED INC looks technically
ELECTROMED INC (ELMD) is trading 27.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 66 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 22 trading days ago. It is 16.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 27.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.26 | $41.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $30.91 | $30.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 43.74. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 66 trading days ago — a "golden cross", a bullish long-term signal | 66 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 40.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($39.26 to $43.74) — its "stochastic" reading is 4 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 4.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $47.38 | $47.38 |
|---|---|---|
| From the 52-week high | it is 16.7% below its 52-week high (its highest price of the past year) | -16.7% |
| Above the 52-week low | it is 109.2% above its 52-week low (its lowest price of the past year) | +109.2% |
| Below the 52-week high | it is 16.7% below its highest point of the past year | 16.7% |
| Since a 20-day breakout | it made a new 20-day low about 22 trading days ago | 22 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $47.38 (set on 2026-07-14) | $47.38 |
| Given back of the 52-week move | over the past year its closes ranged ($19.02 to $46.31), and it has given back roughly a quarter of its rise from last year’s low — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $28.57 to $29.44. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.1% |
| From the all-time high | it is 16.7% below its all-time high | -16.7% |
| Nearest price level | it is trading 10.5% below a resistance level at $43.61 — a price it turned at twice since 2026-08-04, most recently on 2026-08-13. Since 2024-08-21 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +10.5% |
| All-time low | its lowest closing price on record is $0.9015 (set on 2013-09-13) | $0.9015 |
| Above the all-time low | it is 4276.0% above its all-time low | +4,276% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.60 between its high and its low — about 4.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.60 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $39.06 and $43.30 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $39.06 – $41.18 – $43.30 |
| Typical daily range (% of price) | its price moves about 4.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.1% |
| Stretch from the 200-day average | it is trading 5.3 daily ranges above its 200-day average price (27.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.67× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
1
| Gap filled | a 4.4% gap down opened on 2026-07-08 has been "filled" 31 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 31 sessions ago |
|---|
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -4.76% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.0 percentage points (the stock lost 2.6% while the market gained 2.3%) | -5.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.8 percentage points (the stock gained 2.3% while the market gained 3.1%) | -0.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 51.5 percentage points (the stock gained 62.6% while the market gained 11.1%) | +51.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 86.9 percentage points (the stock gained 107.4% while the market gained 20.5%) | +86.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 17.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $34.17 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +15.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-05-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $40.71 — a volume-weighted average of daily closes over 68 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
ELMD last closed at $39.45 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $43.61 | Resistance | 10.5% above the last close | turned there twice · 2026-08-04 to 2026-08-13 |
| $30.61 | Support | 22.4% below the last close | turned there twice · 2025-12-15 to 2026-02-02 |
| $29.79 | Support | 24.5% below the last close | turned there twice · 2024-11-13 to 2026-01-08 |
| $28.06 | Support | 28.9% below the last close | turned there twice · 2025-02-11 to 2025-03-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $43.74.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$40.33 range $36.00 – $45.00; median $40.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Reliance on a single product line (SmartVest) and success in securing healthcare insurance reimbursement for its devices.","Potential changes to government healthcare regulations or reimbursement policies that could adversely affect sales.","Intense competition in the respiratory therapy device market from larger, better-capitalized entities."]
What changed in the latest 10-Q
AI-assisted comparison of ELMD's 10-Q filed 2026-05-12 against the prior one filed 2026-02-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing reports financial results for nine months ended March 31, 2026, compared to nine months ended March 31, 2025
- Newer filing includes breakdown of homecare revenue increase attributing $1,959,000 to higher volume and $671,000 to higher net revenues per approval for three months
- Newer filing includes breakdown of homecare revenue increase attributing $5,699,000 to higher volume and $1,290,000 to higher net revenues per approval for nine months
- Newer filing states averaged 57 homecare field sales representatives for three months ended March 31, 2026
- Newer filing adds detail that hospital revenue growth reflects 'increase in sales representatives focused on the hospital market and higher capital and disposal demand'
- Newer filing provides gross profit percentages of 78.8% and 78.5% for three and nine months ended March 31, 2026
- Removed:
- Older filing reports financial results for six months ended December 31, 2025, compared to six months ended December 31, 2024
- Older filing states averaged 58 homecare field sales representatives for three months ended December 31, 2025
- Older filing includes explanation that hospital revenue decrease in three months was 'due to fewer capital equipment orders as hospital capital revenue is a long-cycle sale'
- Older filing provides gross profit percentages of 78.4% and 78.3% for three and six months ended December 31, 2025
- Reworded:
- Change from 'that require external chest manipulation' to 'that require external chest manipulation' - no material change (identical wording in both texts)
- Change from 'There were no material changes' (older) to 'There have been no material changes' (newer) in Critical Accounting Estimates section
- Older filing states homecare increases were 'primarily due to an increase in direct sales representatives and higher net revenues per sales representative' versus newer filing providing specific dollar and volume attributions
- Notes:
- The two filings cover different reporting periods (nine months ended March 31, 2026 in newer versus six months ended December 31, 2025 in older), making direct financial comparison limited to overlapping narrative content
- The newer filing text appears truncated at the SG&A expenses section, limiting assessment of completeness of differences in Operating Expenses section
Risk Factors
- Added:
- Newer filing (2026-05-12) reports Balance Sheet as of March 31, 2026 compared to June 30, 2025; older filing (2026-02-10) reported Balance Sheet as of December 31, 2025 compared to June 30, 2025
- Newer filing reports nine months ended March 31, 2026 operations; older filing reported six months ended December 31, 2025 operations
- Newer filing Condensed Statements of Cash Flows covers nine months ended March 31, 2026; older filing covered six months ended December 31, 2025
- Newer filing reports income tax receivable of $15,000 at March 31, 2026; older filing reported income tax payable of $382,000 at December 31, 2025
- Removed:
- Older filing's Income tax payable line item ($382,000 at December 31, 2025) does not appear in newer filing's Balance Sheet
- Reworded:
- Condensed Statements of Operations: older filing compared Three Months and Six Months Ended December 31, 2025 vs. 2024; newer filing compared Three Months and Nine Months Ended March 31, 2026 vs. 2025
- Cash Flows statement supplemental disclosure: older filing listed 'Taxes owed on net share settlement of stock awards in accrued liabilities'; newer filing replaced with 'Obligation for unsettled share repurchases in accrued liabilities'
- Notes:
- The two filings cover different fiscal periods (nine months ended March 31, 2026 vs. six months ended December 31, 2025), making some changes reflective of period differences rather than substantive accounting changes
- Risk Factors section headers are identical in both filings; actual Risk Factors text content was not provided for comparison in either filing
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($783032) — 2 selling insiders
- Last 180 days0 buys · 9 sells ($2M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-08. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ELMD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ELMD as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 729,329
- Reported value $17,073,598
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ELMD had 175,926 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ELMD had 2.12% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.8 days to cover at the same settlement.
- Reported short interest (shares) 175,926
- Short interest (% of shares outstanding) 2.12%
- Prior settlement (shares) 194,520
- Reported change -9.56%
- Days to cover (reported) 1.8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Hill-Rom (acquired by Baxter - BAX)
- Philips (PHG)
- ResMed (RMD)
- Vyaire Medical
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ELMD vs…
ELECTROMED INC is found in…
Frequently asked questions
What does ELECTROMED INC (ELMD) do?
Electromed, Inc. designs, manufactures, and markets the SmartVest Airway Clearance System, a therapeutic device that uses high-frequency chest-wall oscillation (HFCWO) technology to help patients with chronic respiratory conditions clear secretions from their airways. The company serves patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), and other conditions requiring airway management.
What sector is ELECTROMED INC (ELMD) in?
ELECTROMED INC (ELMD) is classified in the Health Care sector. Its industry is Medical devices for respiratory care. It trades on NYSE American.
Who are ELECTROMED INC's (ELMD) competitors?
Notable peers of ELECTROMED INC (ELMD) include Hill-Rom (acquired by Baxter - BAX), Philips, ResMed and Vyaire Medical. This peer set is informational only — not financial advice.
Is ELECTROMED INC (ELMD) overbought or oversold right now?
ELECTROMED INC (ELMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ELMD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.